We are international
Donate
• IMF TV TEXT SIZE   
webcasts from medical meetings

Randomized Phase III Study Comparing Conventional-Dose Treatment Using a Combination of Lenalidomide (Revlimid®), Bortezomib (Velcade®), and Dexamethasone (RVD) to High-Dose Treatment with Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

This study, sponsored by Dr. Paul Richardson of the Dana-Farber Cancer Institute, was designed to answer a very important question in myeloma: In the era of novel drugs, is high-dose therapy (HDT) still necessary in the initial management of multiple myeloma in younger patients? In this study, the addition of HDT to conventional dose treatment (RVD) as compared to conventional-dose treatment (RVD) alone would be considered superior if it significantly prolongs progression-free survival by at least 9 months.

08.01.13

Click on the image to view the PDF fileTrial Description: All the drugs used in this trial have been previously approved by the US Food and Drug Administration for the treatment of myeloma, but they have not been approved in this combination. There is strong evidence that this combination is safe and effective in treating newly diagnosed myeloma. The study explores the combination alone or when combined with high-dose chemotherapy (melphalan) and autologous stem cell transplantation. Please note that bortezomib and lenalidomide are provided at no charge to patients who participate in this trial.

Trial Objectives: This study, sponsored by Dr. Paul Richardson of the Dana-Farber Cancer Institute, was designed to answer a very important question in myeloma: In the era of novel drugs, is high-dose therapy (HDT) still necessary in the initial management of multiple myeloma in younger patients? In this study, the addition of HDT to conventionaldose treatment (RVD) as compared to conventional-dose treatment (RVD) alone would be considered superior if it significantly prolongs progression-free survival by at least 9 months.


 related articles